Earnings Releases·Oct 29, 2026, 5:08 PM ET

AptarGroup, Inc. — Third Quarter 2026 Earnings Summary

Reported sales increased 6% year-over-year to $1.02 billion, while reported net income and EPS declined significantly to $33 million and $0.51, respectively, primarily due to a $60.4 million after-tax loss from the deconsolidation of a Russian subsidiary.
Adjusted EPS for the quarter was $1.52 (down from $1.62 prior year), with adjusted EBITDA margin contracting to 21.3% from 23.2%, driven by unfavorable mix and input cost pass-throughs across Beauty and Closures segments.
Management provided Q4 2026 adjusted EPS guidance of $1.39 to $1.47, citing continued Pharma growth in injectables and biologics, while noting ongoing North American operational challenges in Beauty and destocking headwinds in emergency medicine.
Capital return initiatives included $61 million in shareholder returns during the quarter and a subsequent Board approval to increase the quarterly cash dividend from $0.48 to $0.50 per share.